Double‐blind placebo‐controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Plasma levels of dehydroepiandrosterone sulphate (DHEA‐S) decrease with the progression of HIV disease. Here, we report on the efficacy and safety of the oral administration of DHEA as replacement therapy, in patients with advanced HIV disease, in a trial that was primarily aimed at assessing quality of life. DESIGN The trial was randomized and double‐blind. Thirty‐two patients were allocated to either DHEA 50 mg per day for 4 months (n = 14) or a matching placebo (n = 18). Clinical data, virological and immunological surrogate markers of HIV infection, plasma levels of DHEA‐S and the Medical Outcomes Study HIV Health Survey (MOS‐HIV) quality of life scale were recorded every month. RESULTS The mean age of the patients was 40 ± 11 years. The mean CD4 cell count at baseline was 32·5 ± 32·4 × 10 6/l. The mean DHEA‐S plasma level at baseline was 5·23 ± 0·76 µmol/l. No side‐effects related to DHEA occurred during the study. A statistically significant increase in the levels of DHEA‐S was observed in the treated group throughout the study (P < 0·01). A significant improvement in the Mental Health and Health Distress dimension of MOS‐HIV was observed in the DHEA treated group; P = 0·001 and 0·004, respectively. No change in CD4 cell counts was seen during follow‐up. CONCLUSIONS The administration of DHEA in patients with advanced HIV infection results in improved mental function scores as assessed by the MOS‐HIV quality of life scale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
Morales, A. J., Nolan, J. J., Nelson, J. C., & Yen, S. S. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.7515387 · Cited by 841 · cited 7×
“Beneficial effects of replacement therapy with oral DHEA (50 mg/day) have been observed in the elderly (Morales et al., 1994).”
BackgroundResultInfluentialLong-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men
Orentreich, N., Brind, J. L., Vogelman, J. H., Andres, R., & Baldwin, H. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.4.1400863 · Cited by 417
MIGEON, C. J., KELLER, A. R., LAWRENCE, B., & SHEPARD, T. H. (1957) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-17-9-1051 · Cited by 260 · cited 1×
“Serum DHEA-S increases to peak levels during the third decade, and then declines with age (Migeon et al., 1957; Orentreich et al., 1992; Berr et al., 1996).”
BackgroundInhibition of tumor development by dehydroepiandrosterone and related steroids.
Schwartz, A. G., Pashko, L., & Whitcomb, J. M. (1986) · Toxicologic Pathology · doi:10.1177/019262338601400312 · Cited by 101 · cited 2×
“Animal studies have suggested a role for DHEA as providing protection against tumours (Schwartz et al., 1986) and viral infections (Loria et al.”
BackgroundHenderson, E., Yang, J.-Y., & Schwartz, A. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.625 · Cited by 40
Cited by
Mechanick, J. I., Brett, E. M., Chausmer, A. B., Dickey, R. A., Wallach, S., Bergman, D. A., Garber, J. R., Hamilton, C. R., Handelsman, Y., Holdy, K. E., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.417 · Cited by 73
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease.
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-25 · Cited by 54
Libè, R., Barbetta, L., Dall’Asta, C., Salvaggio, F., Gala, C., Beck-Peccoz, P., & Ambrosi, B. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347515 · Cited by 51
Metadata
- Authors
- Piketty, C., Jayle, D., Leplege, A., Castiel, P., Ecosse, E., Gonzalez‐Canali, G., Sabatier, B., Boulle, N., Debuire, B., Le Bouc, Y., Baulieu, E. ‐., & Kazatchkine, M. D.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2001-09
- Volume
- 55
- Issue
- 3
- Pages
- 325-330
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2052875228
- Cited by
- 35
- References
- 5
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐blind placebo‐controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01310.x
- The paper
- Piketty, C., Jayle, D., Leplege, A., Castiel, P., Ecosse, E., Gonzalez‐Canali, G., Sabatier, B., Boulle, N., Debuire, B., Le Bouc, Y., Baulieu, E. ‐., & Kazatchkine, M. D. (2001). Double‐blind placebo‐controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01310.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.